SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioMarin Licenses Fabry Disease Therapy From GC Biopharma and Hanmi

BioMarin says it has worldwide rights, excluding Korea, to investigational enzyme replacement therapy HM15421/GC1134A under an exclusive license agreement with GC Biopharma and Hanmi Pharm.

BMRN
SquawkNews Desk

Related stories

BOJ to Sell ETF Holdings at About 0.1% of Market Trading Value M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC Nikkei Futures Down 2.6% After BOJ Decision Nikkei futures were last down 2.6%, largely unmoved by the BOJ decision. M impact | EQUITY | Oct 30, 2026, 03:03 AM UTC Asian session market picture: S&P 500 -0.99%, Nasdaq 100 -2.2%; USD/JPY -0.12%, WTI +1.28%, 1810 leads volume Asian session market picture. US index futures: S and P futures is down 0.99 percent, Nasdaq futures is down 2.2 percent, Dow futures is down 0.16 percent and Russell futures is do M impact | EQUITY | Oct 30, 2026, 03:00 AM UTC Sarimelati Kencana Attributes Q3 2026 Net Profit Growth to Operating Efficiencies M impact | EQUITY | Oct 30, 2026, 02:58 AM UTC South Korea's Kospi Extends Losses, Down 5.3% at 5,622.84 M impact | EQUITY | Oct 30, 2026, 02:57 AM UTC Nikkei Falls 3% as Technology Shares Slide on AI Concerns The Nikkei fell 3% as technology shares declined amid concerns about artificial intelligence. M impact | EQUITY | Oct 30, 2026, 02:50 AM UTC